*This is a voluntary recall notification in the US and a voluntary field safety notice in other countries.
Understanding the consent decree
The consent decree provides Philips Respironics with a roadmap of defined actions, milestones, and deliverables to meet relevant regulatory requirements.
Strengthening patient safety and quality remains Philips’ highest priority and the company has intensified these efforts to achieve greater benefits for patients, clinicians and customers who rely on Philips’ products and services every day.
Philips is fully committed to complying with the consent decree. Philips CEO Roy Jakobs, as well as Chief Patient Safety and Quality Officer Steve C de Baca and Chief Region Leader Philips North America Jeff DiLullo are responsible for ensuring the remediation actions are delivered by the various teams.
Commenting on the consent decree, Steve C de Baca said:
“Patient safety and quality is our number one priority. We know what we must do to meet the consent decree requirements. Philips Respironics has been working with the FDA, and is already making significant changes in its organization, quality management systems and operations. This includes strengthening the quality management processes and deepening the competencies of the relevant teams. We are fully committed to meeting the terms of the consent decree and continuing to serve the millions of patients who rely on our products and services every day.”
To hear more from Steve C de Baca please click on the video below.
A consent decree is an agreement negotiated between the US government and a company to resolve a dispute between them as an alternative to litigating. In this case, the consent decree is with the FDA and meant to address FDA’s concerns around certain quality-related matters, in part following from an FDA inspection of a Respironics’ manufacturing facility in the US.
Following Philips Respironics’ voluntary recall of certain CPAP and BiPAP sleep therapy devices and ventilators in June 2021, an inspection by FDA of Philips Respironics’ facility in Murrysville in the second half of 2021 and the subsequent inspectional observations, Philips began discussions in July 2022 regarding the terms of a proposed consent decree. Philips’ subsidiaries Philips Holding USA and Philips Respironics have now reached final agreement on the consent decree which primarily focuses on Philips Respironics’ business operations in the US. The decree provides Philips Respironics with a roadmap of defined actions, milestones, and deliverables to demonstrate compliance with regulatory requirements and to restore the business.
Philips’ aim is to serve healthcare providers and their patients with innovative sleep and respiratory products and services. The consent decree provides Philips Respironics with a roadmap of defined actions, milestones, and deliverables to demonstrate compliance with regulatory requirements and to restore the business.
The consent decree will provide Philips Respironics with a roadmap of defined actions, milestones, and deliverables to demonstrate compliance with regulatory requirements and to restore the business. The main terms include:
Outside the US, Philips Respironics will continue to provide new sleep and respiratory care devices, accessories (including masks), consumables (including patient circuits), replacement parts (including repair kits) and services, subject to certain requirements that Philips Respironics will meet.
Related pages
You are about to visit a Philips global content page
Continue